Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for bone health in adults on haemodialysis with end-stage kidney disease
ACTRN12620000321943Phase 3Active, not recruiting
- Sponsor
- Research and Education Network, Westmead Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing Actonel EC with Placebo (2 arms). Primary endpoints: Change in hip bone mineral density and Change in buckling ratio. Started Feb 2022; status: active, not recruiting.
02
Drugs
risedronate sodium delayed-release
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12620000321943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000321943.